Dwight Oliver
YOU?
Author Swipe
View article: Supplementary Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 2). Epithelial and myeloid cell contributions to gene expression and 13C labeling features.
View article: Supplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 3). Overall and recurrence-free survival summary.
View article: Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
13C enrichment in the TCA cycle distinguishes tumors but not benign pulmonary lesions from the adjacent lung. A, Summary of patients with pulmonary lesions. B, Schematic of labeling from [U-13C]glucose, including glycolysis and multiple tu…
View article: Supplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
Key Resources
View article: Supplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 1). TCA cycle labeling and metabolite abundance in tumors and lungs from NSCLC patents.
View article: Supplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 1). Patient Isotopologue Data.
View article: Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
PDXs derived from primary NSCLC retain histological, molecular, and metabolic characteristics. A and B, Summary of histological and molecular characterization of donor tumors (A) and PDX models (B). C, H&E; staining of NSCLC PDXs. D, Engra…
View article: Supplementary Figure 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 4). Development of patient-derived xenografts from malignant tumors in the lung.
View article: Supplementary Table 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 1 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 1). Clinical and pathological data from patients recruited to this study.
View article: Supplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 2). Transcriptomic data for NSCLC and adjacent lung tissue fragments.
View article: Figure 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
PDXs generated from primary NSCLCs spontaneously metastasize in NSG mice. A, Flow cytometry analysis of lung tissue from a mouse engrafted with mx73. Cells were stained with mouse lineage markers (CD45, CD31, and TER119) and HLA. B, Biolum…
View article: Supplementary Table 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
Related to Figures 4 and 6). PDX Isotopologue Data.
View article: Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
Increased 13C enrichment in the TCA cycle predicts reduced survival. A,13C enrichment in the adjacent lung and tumors with high or low TCA cycle labeling. Fractional enrichments of glycolytic (M+3) and TCA cycle (M+2) metabolites are norma…
View article: Supplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 4 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 3). TCA cycle metabolite abundance does not correlate with overall survival.
View article: Data from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Data from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
In patients with non–small cell lung cancer (NSCLC), the relationship between tumor metabolism and clinical outcomes is unknown. Here, 13C-labeled nutrients were intraoperatively infused into more than 90 patients with surgically resectabl…
View article: Supplementary Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figures 5 and 6): Treatment with IACS-010759 reduces distant metastasis.
View article: Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
Cancer cells drive an OXPHOS expression signature in tumors. A, Heatmap of TCA cycle and ETC transcript differences between primary NSCLC and adjacent lung samples. B, RNA scores comparing matched tumor and adjacent lung for the pathways i…
View article: Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
Inhibition of complex I with IACS-010759 limits metastasis in NSCLC PDXs. A and B, Tumor-bearing mice were treated daily with DMSO or IACS-010759 (5 mg/kg) by oral gavage for 3–4 weeks and then infused with [U-13C]glucose for 3 hours. Over…
View article: Supplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
(Related to Figure 3). Relationships between TCA cycle labeling and clinical factors.
View article: High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients Open
In patients with non–small cell lung cancer (NSCLC), the relationship between tumor metabolism and clinical outcomes is unknown. Here, 13C-labeled nutrients were intraoperatively infused into more than 90 patients with surgically resectabl…
View article: Recurrent cytogenetic abnormalities reveal alterations that promote progression and transformation in myelodysplastic syndrome
Recurrent cytogenetic abnormalities reveal alterations that promote progression and transformation in myelodysplastic syndrome Open
This study identified a unique combination of RCAs that are components in distinct cytogenetic trajectories. Some of these were primary changes while others were secondary or tertiary changes. Acquiring specific additional aberrations pred…
View article: Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict <i>IDH</i> mutation in acute myeloid leukemia
Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict <i>IDH</i> mutation in acute myeloid leukemia Open
This study investigates whether serum D‐2HG (D‐2‐hydroxyglutarate) produced by the mutated isocitrate dehydrogenase (IDH) can predict IDH mutations in acute myeloid leukemia (AML) at diagnosis. D‐2HG and L‐2HG are measured by liquid chroma…
View article: Stepped Behavioral and Biological Screening for Oral Oncogenic HPV DNA in Middle-aged and Elderly Adults: A Feasibility Study
Stepped Behavioral and Biological Screening for Oral Oncogenic HPV DNA in Middle-aged and Elderly Adults: A Feasibility Study Open
Novel preventive interventions are needed to address the rising incidence of human papillomavirus (HPV)-mediated oropharyngeal cancer (HPV+ OPC). This pilot study evaluated the feasibility of a stepped, behavioral and biological screening …
View article: Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic PIK3CA Mutation
Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic PIK3CA Mutation Open
Fibro-adipose vascular anomaly (FAVA) is a recently described complex and painful benign lesion found in young adults and the pediatric population composed of intramuscular vascular, fibrous, and adipose tissues. A previous report has iden…
View article: Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern
Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern Open
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge, and effective tracking requires rapid return of results. Surveillance of variants is typically performed by whole genome sequencing (WGS),…
View article: Multiplex Fragment Analysis Identifies SARS-CoV-2 Variants
Multiplex Fragment Analysis Identifies SARS-CoV-2 Variants Open
The rapid spread of SARS-CoV-2 Variants of Concern (VOC) necessitates systematic efforts for epidemiological surveillance. The current method for identifying variants is viral whole genome sequencing (WGS). Broad clinical adoption of seque…
View article: Digital Droplet PCR for SARS-CoV-2 Resolves Borderline Cases
Digital Droplet PCR for SARS-CoV-2 Resolves Borderline Cases Open
Objectives The Bio-Rad SARS-CoV-2 ddPCR Kit (Bio-Rad Laboratories) was the first droplet digital polymerase chain reaction (ddPCR) assay to receive Food and Drug Administration (FDA) Emergency Use Authorization approval, but it has not bee…